BioInsights - Key considerations when adopting Droplet Digital PCR for viral vector manufacture

Key considerations when adopting Droplet Digital PCR for viral vector manufacture

Cell & Gene Therapy Insights 2022; 8(1), 161;

10.18609/cgti.2022.007

Published: 24 February 2022
FastFacts
Mark White

Increase your knowledge of: 

  • The crucial considerations when transitioning into ddPCR from a different platform. 
  • The additional key areas in which ddPCR is beginning to be applied and the impact made. 
  • The key issues and standardization requirements that are relevant to the various specific applications of ddPCR.

Mark White is the Associate Director of Biopharma Product Marketing at Bio-Rad. He has played a key role in the development of multiple core technology capabilities and assays alongside a multidisciplinary team of biologists and engineers at Bio-Rad and previously at Berkeley Lights Inc.. Mark obtained his Ph.D. in Biomedical Sciences at the University of California, San Francisco.